Morningside Ventures is a long-established venture capital firm based in the Boston area, investing across life sciences, medtech, digital health, and AI. It participates mainly from Series A through Series C and has become one of the more active generalist healthcare investors with real depth in neuroscience and neurotechnology. Its profile is stronger in neuro than many similarly broad life sciences funds.

Its portfolio includes companies such as Ampa Health, Cognito Therapeutics, Neuroelectrics, and Linus Health. These investments span brain stimulation, gamma entrainment for Alzheimer’s disease, neurodiagnostics, and cognitive screening, showing clear breadth across clinical neurotechnology. Morningside stands out because it has repeatedly taken serious positions in neuroscience-focused businesses rather than treating the area as incidental.

The firm primarily invests in North America, especially the Boston ecosystem, while maintaining broader global reach. For neurotech founders, it is a highly relevant investor for clinical-stage brain health companies across therapeutics, diagnostics, and device-enabled care. It is one of the stronger generalist healthcare funds for founders specifically working in neuroscience.